



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/613,785
	Filing Date	July 3, 2003
	First Named Inventor	Jolidon, et al.
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21288 US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	-Copies of References B1-B3, and C1-C11	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Kimberly J. Prior
Signature	
Date	October 1, 2003

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date <u>October 1, 2003</u>			
Typed or printed	Kimberly J. Prior		
Signature		Date	October 1, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Jolidon, et al.

Serial No. 10/613,785, filed July 3, 2003
(Ref. No. 21288 US)

For: **3-PHENYL-PROPIONAMIDO, 3-PHENYL-ACRYLAMIDO AND 3-PHENYL-
PROPYNAMIDO DERIVATIVES**

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
October 1, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1-B3, and C1-C11, listed on Form PTO-1449 are enclosed.

Serial No. 10/613,785
Filed: July 3, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

A handwritten signature in cursive script, reading "Kimberly J. Prior", written over a horizontal line.

Attorney for Applicant(s)

Kimberly J. Prior


(Reg. No. 41,483)

340 Kingsland Street

Nutley, New Jersey 07110

Telephone: (973) 235-6208

Telefax: (973) 235-2363



Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/613,785		
				Filing Date	July 3, 2003		
				First Name Inventor	Jolidon, et al.		
Sheet	1	of	1	Attorney Docket Number	21288 US		
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	A						
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ³
		Office ⁴	Number	Kind Code ⁵ (if known)			
	B1		WO 01/34172		VELA PHARMACEUTICALS INC.	05/17/2001	
	B2		WO 97/33572		SOMERSET PHARMACEUTICALS, INC.	09/18/1997	
	B3		WO 96/40095		HARRIS, RICHARD, Y.	12/19/1996	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Benedetti et al., Biochem Pharmacol. Vol. 38: No. 4 p. 555-561 (1989)	
	C2	Saura et al., Neuroscience Vol. 70: No. 3, p. 755-774 (1996)	
	C3	Bentu� Ferrer et al., CNS Drugs 6: p. 217-236 (1996)	
	C4	Gardner et al., J. Clin. Psychiatry Vol. 57: No. 3, p. 99-104 (1996)	
	C5	Greenspan et al. J. Med. Chem. 42: p. 164-172 (1999)	
	C6	Drechsler et al., Eur. J. Org. Chem. p. 3441-3453 (1999)	
	C7	Austin et al., J. Org. Chem. 46: p. 2280-2286 (1981)	
	C8	Eckert et al., Synth. Commun. 28(2), p. 327-335 (1998)	
	C9	Schlaeger & Christensen, Cytotechnology Vol. 30: p. 71-83 (1999)	
	C10	Zhou & Panchuk-Voloshina, Analytical Biochemistry Vol. 253: p. 169-174 (1997)	
	C11	Jaen, J. et al., J. Med. Chem. 31: p. 1621-1625 (1988)	

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

134759